149805-92-5

Usage

Uses

Used in Pharmaceutical Production:
6-(DIMETHYLAMINO)NICOTINALDEHYDE is utilized as an intermediate in the synthesis of pharmaceuticals, leveraging its capacity to participate in a variety of chemical reactions to create diverse medicinal compounds.
Used in Organic Synthesis:
In the realm of organic chemistry, 6-(DIMETHYLAMINO)NICOTINALDEHYDE serves as a key component in the synthesis of various organic compounds, contributing to the creation of new molecules with potential applications across different industries.
Used in Chemical Reactions as a Reagent:
6-(DIMETHYLAMINO)NICOTINALDEHYDE is employed as a reagent in chemical reactions, capitalizing on its reactive properties to facilitate the formation of desired products in the synthesis process.
Used in Research and Development:
6-(DIMETHYLAMINO)NICOTINALDEHYDE is also used in research and development settings to explore new chemical pathways and develop innovative applications, further expanding its utility in the scientific community.

InChI:InChI=1/C8H10N2O/c1-10(2)8-4-3-7(6-11)5-9-8/h3-6H,1-2H3

Upstream product

• 26163-07-5 5-bromo-2-dimethylaminopyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 5683-33-0 2-(Dimethylamino)pyridine 
• 20485-44-3 2,3-dimethyl-2,3-diaminobutane 
• 23100-12-1 6-chloronicotinylaldehyde 
• 124-40-3 dimethyl amine 
• 154924-17-1 N'-(5-cyanopyridin-2-yl)-N,N-dimethylformamidine 

Downstream Products

• 1620092-89-8 (E)-5-(2,6-dichlorostyryl)-2-(N,N-dimethylamino)pyridine 
• 1620092-87-6 (E)-5-(2-chloro-6-fluorostyryl)-2-(N,N-dimethylamino)pyridine 
• 1620092-84-3 (E)-5-(2,6-difluorostyryl)-2-(N,N-dimethylamino)pyridine 
• 1428970-00-6 2-(6-(dimethylamino)pyridin-3-yl)-1-(1H-indol-3-yl)-2-((3-methoxyphenyl)amino)ethanone 
• 1428973-28-7 5-(((3-methoxyphenyl)imino)methyl)-N,N-dimethylpyridin-2-amine 
• 1349698-33-4 tert-butyl (4-{(E)-2-[6-(dimethylamino)pyridin-3-yl]vinyl}phenyl)methylcarbamate 

Relevant academic research and scientific papers

COMPOUND, ADHESIVE COMPOSITION, POLARIZER AND DISPLAY APPARATUS

The present specification relates to a compound represented by chemical formula 1, an adhesive composition comprising the same, a polarizing plate, and an image display apparatus. By using the compound described in the present specification as the adhesive composition for the polarizing plate, it is possible to provide the adhesive composition having excellent UV blocking performance and exhibiting excellent durability.

MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)

The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.

Synthesis and luminescence properties of near-infrared N-heterocyclic luciferin analogues for in vivo optical imaging

As a means of achieving highly sensitive bioluminescence imaging of deep tissues utilizing the firefly luciferin-luciferase (L-L) reaction, we previously reported a luciferin analogue, AkaLumine, which exhibits high cell-permeability and emits near-infrar

NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE

The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj?gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

NOVEL HETEROCYCLIC COMPOUNDS AND SALTS THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITIONS

PROBLEM TO BE SOLVED: To provide novel compounds excellent in solubility in a buffer solution having a near-neutral pH and available as luminescent substrates in firefly bioluminescence systems. SOLUTION: The present invention provides heterocyclic compou

Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylamino- pyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure-activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists

We previously shown that 3-phenylpyrazolo[1,5-a]pyrimidines exemplified by 8 were potent antagonists of the human corticotropin-releasing factor-1 receptor. A series of 3-pyridylpyrazolo-[1,5-a]pyrimidines 15, 25-30, 34, and 35 containing a weakly basic pyridine ring at the 3-position of the bicyclic nucleus was designed to reduce lipophilicity from the initial leads such as 7. Here, we showed that these 3-pyridyl compounds exhibited potent antagonists at the human CRF1 receptor. Moreover, the hydrophilic and weakly basic pyridine moiety increased the water solubility of some analogues. Compound 26h exhibited good binding affinity at the human CRF1 receptor with a Ki value of 3.5 nM. As a functional antagonist, it dose-dependently inhibited CRF-stimulated cAMP production in cells expressing the CRF1 receptor (IC50 = 50 nM), and CRF-stimulated ACTH release from cultured rat pituitary cells (IC50 = 20 nM). 26h had a log P value of 4.9 and water solubility of greater than 10 mg/mL. Pharmacokinetic studies in rats showed that 26h was orally bioavailable and able to penetrate into the brain. 26h has been demonstrated in vivo efficacy in animal behavioral models that measure anxiolytic activity. These results suggest that analogues from this series were potent CRF1 receptor antagonists with proper physicochemical properties and good pharmacokinetic profiles. 26h was developed into a clinical compound and exhibited efficacy in patients with major depression.